Entry ID,Ligand,Value,Symbol,Type,Unit,PDB ID,Title,Structure Title,Stucture Keywords,Gene Name,EC Number,Annotation Identifier,Entity ID,Entry Id (Polymer Entity Identifiers),Target Protein,Accession Code(s),Database Name,Ligand Formula,Ligand MW,Ligand ID,Ligand Name,Ligand SMILES,Entity ID
7QXN,,,,,,7QXN,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+A state,STRUCTURAL PROTEIN,"SEM1, C7orf76, DSS1, SHFDG1, SHFM1",,"GO:0005829, GO:0005654, GO:0000502, GO:0008541, GO:0032991, GO:0000724, GO:0006406, GO:0043248, GO:0043161, IPR007834",11,7QXN,wildtype,P60896,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXN,,,,,,7QXN,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+A state,STRUCTURAL PROTEIN,"PSMD2, TRAP2",,"GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008540, GO:0034515, GO:0034774, GO:0030234, GO:0043161, GO:0042176, IPR016643, IPR011989, IPR016024, IPR002015, IPR041433, IPR040892, Q13200",12,7QXN,wildtype,Q13200,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXP,,,,,,7QXP,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+B state,STRUCTURAL PROTEIN,PSMD8,,"GO:0005829, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008541, GO:0043161, IPR006746, IPR033464, IPR000717, P48556",10,7QXP,wildtype,P48556,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXP,,,,,,7QXP,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+B state,STRUCTURAL PROTEIN,"PSMD2, TRAP2",,"GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008540, GO:0034515, GO:0034774, GO:0030234, GO:0043161, GO:0042176, IPR016643, IPR011989, IPR016024, IPR002015, IPR041433, IPR040892, Q13200",12,7QXP,wildtype,Q13200,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXU,,,,,,7QXU,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+C state,STRUCTURAL PROTEIN,PSMD1,,"GO:0035578, GO:0005829, GO:0005576, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008540, GO:0034515, GO:0030234, GO:0031625, GO:0043161, GO:0042176, IPR016642, IPR011989, IPR016024, IPR002015, IPR035266, IPR040623, Q99460",1,7QXU,wildtype,Q99460,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXU,,,,,,7QXU,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+C state,STRUCTURAL PROTEIN,"SEM1, C7orf76, DSS1, SHFDG1, SHFM1",,"GO:0005829, GO:0005654, GO:0000502, GO:0008541, GO:0032991, GO:0000724, GO:0006406, GO:0043248, GO:0043161, IPR007834",11,7QXU,wildtype,P60896,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QXW,,,,,,7QXW,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+D state,STRUCTURAL PROTEIN,PSMD8,,"GO:0005829, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008541, GO:0043161, IPR006746, IPR033464, IPR000717, P48556",10,7QXW,wildtype,P48556,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,35
7QXW,,,,,,7QXW,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+D state,STRUCTURAL PROTEIN,"PSMC2, MSS1",,"GO:0005737, GO:0036464, GO:0005829, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005634, GO:0000932, GO:0022624, GO:0000502, GO:0008540, GO:0034774, GO:0005524, GO:0016887, GO:0036402, GO:0001649, GO:1901800, GO:0043161, GO:0006511, IPR005937, IPR003593, IPR041569, IPR003959, IPR003960, IPR012340, IPR027417, IPR035245, P35998",12,7QXW,wildtype,P35998,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,37
7QXX,,,,,,7QXX,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+E state,STRUCTURAL PROTEIN,PSMB2,3.4.25.1,"GO:0005737, GO:0005829, GO:0070062, GO:0016020, GO:0005654, GO:0005634, GO:0000502, GO:0005839, GO:0019774, GO:0010498, GO:0043161, GO:0014070, GO:0010243, IPR029055, IPR035206, IPR016050, IPR001353, IPR023333, P49721",29,7QXX,wildtype,P49721,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QXX,,,,,,7QXX,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z+E state,STRUCTURAL PROTEIN,PSMD1,,"GO:0035578, GO:0005829, GO:0005576, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008540, GO:0034515, GO:0030234, GO:0031625, GO:0043161, GO:0042176, IPR016642, IPR011989, IPR016024, IPR002015, IPR035266, IPR040623, Q99460",1,7QXX,wildtype,Q99460,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7QY7,,,,,,7QY7,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND6,Proteasome-ZFAND6 Complex Z-A state,STRUCTURAL PROTEIN,PSMD13,,"GO:0005829, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008541, GO:0034774, GO:0005198, GO:0007127, GO:0043161, GO:0006511, IPR000717, IPR035298, IPR036390, Q9UNM6",1,7QY7,wildtype,Q9UNM6,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYA,,,,,,7QYA,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-B state,STRUCTURAL PROTEIN,PSMD11,,"GO:0005829, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0008541, GO:0034774, GO:0005198, GO:0043248, GO:0043161, GO:0048863, GO:0006511, IPR000717, IPR035295, IPR040780, IPR040773, IPR011990, IPR036390, O00231",10,7QYA,wildtype,O00231,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYB,,,,,,7QYB,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-C state,STRUCTURAL PROTEIN,PSMD1,,"GO:0035578, GO:0005829, GO:0005576, GO:0016020, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008540, GO:0034515, GO:0030234, GO:0031625, GO:0043161, GO:0042176, IPR016642, IPR011989, IPR016024, IPR002015, IPR035266, IPR040623, Q99460",1,7QYB,wildtype,Q99460,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,34
7QYB,,,,,,7QYB,Mechanism of 26S proteasome activation by the 19S-interacting protein ZFAND5,Proteasome-ZFAND5 Complex Z-C state,STRUCTURAL PROTEIN,PSMD8,,"GO:0005829, GO:0005654, GO:0005634, GO:0022624, GO:0000502, GO:0005838, GO:0008541, GO:0043161, IPR006746, IPR033464, IPR000717, P48556",10,7QYB,wildtype,P48556,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,36
7TTZ,,,,,,7TTZ,Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.,Heterodimeric IgA Fc in complex with Staphylococcus aureus protein SSL7,IMMUNE SYSTEM,DKFZp686L19235,,"GO:0016020, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR003599, IPR003598, IPR013106",1,7TTZ,mutant,Q6MZV6,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7TTZ,,,,,,7TTZ,Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics.,Heterodimeric IgA Fc in complex with Staphylococcus aureus protein SSL7,IMMUNE SYSTEM,DKFZp686L19235,,"GO:0016020, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, IPR003599, IPR003598, IPR013106",2,7TTZ,mutant,Q6MZV6,UniProt,C11 H24 O6,252.305,1PG,2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL,COCCOCCOCCOCCOCCO,5
7TUO,,,,,,7TUO,Crystal Structure Analysis of human USP28 complex with a compound,Crystal structure analysis of human USP28 complex with a compound,HYDROLASE/HYDROLASE INHIBITOR,"USP28, KIAA1515",3.4.19.12,"GO:0005829, GO:0016604, GO:0005654, GO:0005634, GO:0032991, GO:0004843, GO:0004197, GO:0008283, GO:0006974, GO:0034644, GO:0000077, GO:0006281, GO:0042771, GO:0016579, GO:0007265, GO:0031647, GO:0010212, GO:0006511, IPR038765, IPR001394, IPR009060, IPR018200, IPR028889, Q96RU2",1,7TUO,wildtype,Q96RU2,UniProt,C23 H27 N5 O S,421.558,KL9,"7-amino-N-(2-{4-[(1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl]phenyl}ethyl)-3-methylthieno[2,3-b]pyrazine-6-carboxamide",Cc1cnc2c(c(sc2n1)C(=O)NCCc3ccc(cc3)C4CC5CCC(C4)N5)N,2
7TVA,,,,,,7TVA,A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.,Stat5a Core in complex with AK2292,TRANSCRIPTION,"STAT5A, STAT5",,"GO:0000785, GO:0005829, GO:0005654, GO:0090575, GO:0003700, GO:0000981, GO:0140297, GO:0000978, GO:0019221, GO:0006952, GO:0060397, GO:0007595, GO:0043536, GO:0001938, GO:0045944, GO:0007259, GO:0038026, GO:0042127, GO:0040014, GO:0006357, GO:0043434, GO:0019530, IPR008967, IPR000980, IPR036860, IPR001217, IPR035858, IPR036535, IPR013800, IPR015988, IPR013801, IPR012345, IPR013799, P42229",1,7TVA,wildtype,P42229,UniProt,C52 H54 F2 N7 O10 P S2,1070.127,KOO,"N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N-(5-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}pent-4-yn-1-yl)-N-methyl-N~3~-[4-(1,3-thiazol-2-yl)phenyl]-beta-alaninamide",CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)CCCC#Cc2cccc3c2CN(C3=O)C4CCC(=O)NC4=O)c5ccc(cc5)c6nccs6)NC(=O)c7cc8cc(ccc8s7)C(F)(F)P(=O)(O)O,2
7TVB,,,,,,7TVB,A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.,Stat5A Core in Complex with AK305,TRANSCRIPTION,"STAT5A, STAT5",,"GO:0000785, GO:0005829, GO:0005654, GO:0090575, GO:0003700, GO:0000981, GO:0140297, GO:0000978, GO:0019221, GO:0006952, GO:0060397, GO:0007595, GO:0043536, GO:0001938, GO:0045944, GO:0007259, GO:0038026, GO:0042127, GO:0040014, GO:0006357, GO:0043434, GO:0019530, IPR008967, IPR000980, IPR036860, IPR001217, IPR035858, IPR036535, IPR013800, IPR015988, IPR013801, IPR012345, IPR013799, P42229",1,7TVB,wildtype,P42229,UniProt,C35 H40 F2 N5 O7 P S2,775.822,KOC,"N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N,N-dimethyl-N~3~-[4-(1,3-thiazol-2-yl)phenyl]-beta-alaninamide",CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc(cc2)c3nccs3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,2
7UBT,,,,,,7UBT,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 18,TRANSCRIPTION/INHIBITOR,"STAT5A, STAT5",,"GO:0000785, GO:0005829, GO:0005654, GO:0090575, GO:0003700, GO:0000981, GO:0140297, GO:0000978, GO:0019221, GO:0006952, GO:0060397, GO:0007595, GO:0043536, GO:0001938, GO:0045944, GO:0007259, GO:0038026, GO:0042127, GO:0040014, GO:0006357, GO:0043434, GO:0019530, IPR008967, IPR000980, IPR036860, IPR001217, IPR035858, IPR036535, IPR013800, IPR015988, IPR013801, IPR012345, IPR013799, P42229",1,7UBT,wildtype,P42229,UniProt,C33 H38 F2 N5 O7 P S2,749.785,MIW,"N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(1,3-benzothiazol-5-yl)-N,N-dimethyl-beta-alaninamide",CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc3c(c2)ncs3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,3
7UC6,,,,,,7UC6,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 12,TRANSCRIPTION/INHIBITOR,"STAT5A, STAT5",,"GO:0000785, GO:0005829, GO:0005654, GO:0090575, GO:0003700, GO:0000981, GO:0140297, GO:0000978, GO:0019221, GO:0006952, GO:0060397, GO:0007595, GO:0043536, GO:0001938, GO:0045944, GO:0007259, GO:0038026, GO:0042127, GO:0040014, GO:0006357, GO:0043434, GO:0019530, IPR008967, IPR000980, IPR036860, IPR001217, IPR035858, IPR036535, IPR013800, IPR015988, IPR013801, IPR012345, IPR013799, P42229",1,7UC6,wildtype,P42229,UniProt,C32 H38 Br F2 N4 O7 P S,771.606,MJ6,"N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(4-bromophenyl)-N,N-dimethyl-beta-alaninamide",CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc(cc2)Br)NC(=O)c3cc4cc(ccc4s3)C(F)(F)P(=O)(O)O,2
7UC7,,,,,,7UC7,Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.,Stat5a Core in complex with Compound 17,TRANSCRIPTION/INHIBITOR,"STAT5A, STAT5",,"GO:0000785, GO:0005829, GO:0005654, GO:0090575, GO:0003700, GO:0000981, GO:0140297, GO:0000978, GO:0019221, GO:0006952, GO:0060397, GO:0007595, GO:0043536, GO:0001938, GO:0045944, GO:0007259, GO:0038026, GO:0042127, GO:0040014, GO:0006357, GO:0043434, GO:0019530, IPR008967, IPR000980, IPR036860, IPR001217, IPR035858, IPR036535, IPR013800, IPR015988, IPR013801, IPR012345, IPR013799, P42229",1,7UC7,wildtype,P42229,UniProt,C34 H39 F2 N4 O8 P S,732.731,MQX,"N-{5-[difluoro(phosphono)methyl]-1-benzothiophene-2-carbonyl}-3-methyl-L-valyl-L-prolyl-N~3~-(1-benzofuran-5-yl)-N,N-dimethyl-beta-alaninamide",CC(C)(C)C(C(=O)N1CCCC1C(=O)N(CCC(=O)N(C)C)c2ccc3c(c2)cco3)NC(=O)c4cc5cc(ccc5s4)C(F)(F)P(=O)(O)O,3
7UV9,,,,,,7UV9,Structural basis of paralog-specific KDM2A/B nucleosome recognition.,KDM2A-nucleosome structure stabilized by H3K36C-UNC8015 covalent conjugate,GENE REGULATION/DNA,"H3C15, HIST2H3A, H3C14, H3F2, H3FM, HIST2H3C, H3C13, HIST2H3D",,"GO:0070062, GO:0005576, GO:0005654, GO:0000786, GO:0005634, GO:0003677, GO:0046982, GO:0030527, GO:0006334, IPR009072, IPR007125, IPR000164, Q71DI3",1,7UV9,mutant,Q71DI3,UniProt,C10 H19 N O4,217.262,OH0,N-heptanoyl-N-hydroxy-beta-alanine,CCCCCCC(=O)N(CCC(=O)O)O,8
7UVA,,,,,,7UVA,Structural basis of paralog-specific KDM2A/B nucleosome recognition.,Crystal structure of KDM2A histone demethylase catalytic domain in complex with an H3C36 peptide modified by UNC8015,GENE REGULATION,"Kdm2a, Fbl11, Fbxl11, Jhdm1a, Kiaa1004",1.14.11.27,"GO:0000785, GO:0005654, GO:0032452, GO:0140680, GO:0051864, GO:0003712, GO:0045322, GO:0008270, GO:0006325, GO:0032922, GO:0006303, GO:0001947, GO:0070544, GO:0001701, GO:0035264, GO:0043066, GO:0010629, GO:0010944, GO:0001843, GO:0060563, GO:0030182, GO:0010628, GO:0033184, GO:0006482, GO:0042752, GO:0006357, IPR001810, IPR041070, IPR003347, IPR006553, IPR032675, IPR019786, IPR002857, IPR011011, IPR001965, IPR019787, IPR013083, P59997",2,7UVA,wildtype,P59997,UniProt,C10 H19 N O4,217.262,OH0,N-heptanoyl-N-hydroxy-beta-alanine,CCCCCCC(=O)N(CCC(=O)O)O,5
7UXL,,,,,,7UXL,"Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.",Crystal structure of malaria transmission-blocking antigen Pfs48/45-6C variant in complex with human antibodies RUPA-44 and RUPA-29,IMMUNE SYSTEM,,,,1,7UXL,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7W41,,,,,,7W41,Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy.,Crystal Structure of Human Gastrin Releasing Peptide Receptor in complex with the antagonist PD176252,MEMBRANE PROTEIN,GRPR,,"GO:0005886, GO:0008528, GO:0004930, GO:0042923, GO:0008188, GO:0007186, GO:0007611, GO:0061744, GO:0007200, GO:2000987, GO:1903942, GO:0036343, GO:0042127, GO:0043207, GO:0035176, IPR001556, IPR001966, IPR000276, IPR017452, GO:0004373, GO:0000166, IPR001296, IPR011835, IPR013534, P30550, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.Gastrin Releasing Peptide Receptor (GRPR) - G<sub>q</sub> complex with bound agonist GRP, Generic PDBTM",1,7W41,mutant,P30550,UniProt,C32 H36 N6 O5,584.665,8B8,(2S)-3-(1H-indol-3-yl)-N-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide,CC(Cc1c[nH]c2c1cccc2)(C(=O)NCC3(CCCCC3)c4ccc(cn4)OC)NC(=O)Nc5ccc(cc5)[N+](=O)[O-],2
7WR9,,,,,,7WR9,Local CryoEM structure of the SARS-CoV S2P in complex with BD55-3152 Fab,Local CryoEM structure of the SARS-CoV S2P in complex with BD55-3152 Fab,VIRAL PROTEIN,,,,1,7WR9,wildtype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WUZ,,,,,,7WUZ,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,OXIDOREDUCTASE,MMACHC,"2.5.1.151, 1.16.1.6","GO:0005737, GO:0005829, GO:0031419, GO:0033787, GO:0032451, GO:0071949, GO:0043295, GO:0016491, GO:0042803, GO:0016740, GO:0009235, GO:0070988, GO:0006749, IPR032037, Q9Y4U1",1,7WUZ,wildtype,Q9Y4U1,UniProt,C4 H6 O6,150.087,TLA,L(+)-TARTARIC ACID,C(C(C(=O)O)O)(C(=O)O)O,3
7WUZ,,,,,,7WUZ,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin,OXIDOREDUCTASE,MMACHC,"2.5.1.151, 1.16.1.6","GO:0005737, GO:0005829, GO:0031419, GO:0033787, GO:0032451, GO:0071949, GO:0043295, GO:0016491, GO:0042803, GO:0016740, GO:0009235, GO:0070988, GO:0006749, IPR032037, Q9Y4U1",1,7WUZ,wildtype,Q9Y4U1,UniProt,C63 H89 Co N14 O14 P,1356.373,CNC,CYANOCOBALAMIN,Cc1cc2c(cc1C)n(cn2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C7=[N]6[Co+2]89(N5C4=C(C1=[N]8C(=CC2=[N]9C(=C7C)C(C2CCC(=O)N)(C)CC(=O)N)C(C1CCC(=O)N)(C)C)C)C#N)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,2
7WWI,,,,,,7WWI,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7WWI,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WWJ,,,,,,7WWJ,EM structure of SARS-CoV-2 Omicron variant spike glycoprotein and 55A8,SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 2 conformation,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7WWJ,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
7WZ3,,,,,,7WZ3,Pathway and mechanism of tubulin folding mediated by TRiC/CCT conjugated with its ATPase cycle revealed by cryo-EM,Cryo-EM structure of human TRiC-tubulin-S1 state,STRUCTURAL PROTEIN,"TCP1, CCT1, CCTA",,"GO:0001669, GO:0044297, GO:0005813, GO:0005832, GO:0005829, GO:0070062, GO:0005794, GO:0000792, GO:0005874, GO:0000242, GO:0002199, GO:0005524, GO:0016887, GO:0140662, GO:0044183, GO:0003723, GO:0031625, GO:0051082, GO:0007339, GO:0061077, GO:1904851, GO:1904871, GO:0051973, GO:1904874, GO:0032212, GO:0006457, GO:0050821, GO:2000109, GO:0090666, GO:1901998, GO:0044053, GO:0007021, IPR012715, IPR017998, IPR002194, IPR002423, IPR027409, IPR027413, IPR027410, P17987",1,7WZ3,mutant,P17987,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7X8P,,,,,,7X8P,An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies.,Frizzled 2 CRD in complex with pF7_A5 Fab,SIGNALING PROTEIN,FZD2,,"GO:0030669, GO:0005737, GO:0005925, GO:0005886, GO:0004930, GO:0030165, GO:0042813, GO:0017147, GO:0060070, GO:0090103, GO:0045446, GO:0060022, GO:0060119, GO:0003149, GO:0003150, GO:0030182, GO:0003151, GO:0090179, GO:0051091, GO:0045893, GO:0007608, GO:0016055, GO:0060071, IPR015526, IPR000539, IPR020067, IPR036790, IPR041778, IPR026550, IPR017981, Q14332",1,7X8P,wildtype,Q14332,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7X8P,,,,,,7X8P,An epitope-directed selection strategy facilitating the identification of Frizzled receptor selective antibodies.,Frizzled 2 CRD in complex with pF7_A5 Fab,SIGNALING PROTEIN,FZD2,,"GO:0030669, GO:0005737, GO:0005925, GO:0005886, GO:0004930, GO:0030165, GO:0042813, GO:0017147, GO:0060070, GO:0090103, GO:0045446, GO:0060022, GO:0060119, GO:0003149, GO:0003150, GO:0030182, GO:0003151, GO:0090179, GO:0051091, GO:0045893, GO:0007608, GO:0016055, GO:0060071, IPR015526, IPR000539, IPR020067, IPR036790, IPR041778, IPR026550, IPR017981, Q14332",2,7X8P,wildtype,Q14332,UniProt,C16 H30 O2,254.408,PAM,PALMITOLEIC ACID,CCCCCCC=CCCCCCCCC(=O)O,5
7XQB,,,,,,7XQB,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs at pH ~8.0,MEMBRANE PROTEIN,"GJA1, GJAL",,"GO:0016324, GO:0030054, GO:0044291, GO:0005922, GO:0005737, GO:0005789, GO:0005925, GO:0005921, GO:0005794, GO:0000139, GO:0030660, GO:0014704, GO:0043231, GO:0045121, GO:0005739, GO:0005654, GO:0005634, GO:0005886, GO:0070160, GO:0043014, GO:0008013, GO:0015562, GO:0005243, GO:0086075, GO:1903763, GO:0055077, GO:0034634, GO:0015075, GO:0015631, GO:0086014, GO:0060348, GO:0046849, GO:0003161, GO:0010644, GO:0086064, GO:0007267, GO:1904646, GO:0000132, GO:0140115, GO:0016264, GO:0014047, GO:0034220, GO:0035633, GO:0099111, GO:0030308, GO:0032277, GO:1901164, GO:0120162, GO:0010628, GO:0043123, GO:1905772, GO:1905332, GO:2000648, GO:1904707, GO:0008104, GO:0007165, GO:0007283, GO:0042908, IPR035091, IPR000500, IPR002261, IPR013124, IPR034634, IPR019570, IPR017990, IPR013092, IPR038359, P17302, Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin, Generic PDBTM",1,7XQB,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,3
7XQD,,,,,,7XQD,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs (C1 symmetry),MEMBRANE PROTEIN,"GJA1, GJAL",,"GO:0016324, GO:0030054, GO:0044291, GO:0005922, GO:0005737, GO:0005789, GO:0005925, GO:0005921, GO:0005794, GO:0000139, GO:0030660, GO:0014704, GO:0043231, GO:0045121, GO:0005739, GO:0005654, GO:0005634, GO:0005886, GO:0070160, GO:0043014, GO:0008013, GO:0015562, GO:0005243, GO:0086075, GO:1903763, GO:0055077, GO:0034634, GO:0015075, GO:0015631, GO:0086014, GO:0060348, GO:0046849, GO:0003161, GO:0010644, GO:0086064, GO:0007267, GO:1904646, GO:0000132, GO:0140115, GO:0016264, GO:0014047, GO:0034220, GO:0035633, GO:0099111, GO:0030308, GO:0032277, GO:1901164, GO:0120162, GO:0010628, GO:0043123, GO:1905772, GO:1905332, GO:2000648, GO:1904707, GO:0008104, GO:0007165, GO:0007283, GO:0042908, IPR035091, IPR000500, IPR002261, IPR013124, IPR034634, IPR019570, IPR017990, IPR013092, IPR038359, P17302, Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin, Generic PDBTM",1,7XQD,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,4
7XQF,,,,,,7XQF,Conformational changes in the human Cx43/GJA1 gap junction channel visualized using cryo-EM.,Structure of C-terminal truncated connexin43/Cx43/GJA1 gap junction intercellular channel in POPE/CHS nanodiscs,MEMBRANE PROTEIN,"GJA1, GJAL",,"GO:0016324, GO:0030054, GO:0044291, GO:0005922, GO:0005737, GO:0005789, GO:0005925, GO:0005921, GO:0005794, GO:0000139, GO:0030660, GO:0014704, GO:0043231, GO:0045121, GO:0005739, GO:0005654, GO:0005634, GO:0005886, GO:0070160, GO:0043014, GO:0008013, GO:0015562, GO:0005243, GO:0086075, GO:1903763, GO:0055077, GO:0034634, GO:0015075, GO:0015631, GO:0086014, GO:0060348, GO:0046849, GO:0003161, GO:0010644, GO:0086064, GO:0007267, GO:1904646, GO:0000132, GO:0140115, GO:0016264, GO:0014047, GO:0034220, GO:0035633, GO:0099111, GO:0030308, GO:0032277, GO:1901164, GO:0120162, GO:0010628, GO:0043123, GO:1905772, GO:1905332, GO:2000648, GO:1904707, GO:0008104, GO:0007165, GO:0007283, GO:0042908, IPR035091, IPR000500, IPR002261, IPR013124, IPR034634, IPR019570, IPR017990, IPR013092, IPR038359, P17302, Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin, Generic PDBTM",1,7XQF,wildtype,P17302,UniProt,C31 H50 O4,486.726,Y01,CHOLESTEROL HEMISUCCINATE,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,4
7YCN,,,,,,7YCN,Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.,Crystal structure of SARS-CoV-2 Spike RBD in complex with IY-2A Fab,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,7YCN,wildtype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
7YSG,,,,,,7YSG,Immunoglobulin M perception by Fc mu R.,Cryo-EM structure of human FcmR bound to sIgM,IMMUNE SYSTEM,IGHM,,"GO:0072562, GO:0009986, GO:0009897, GO:0070062, GO:0005615, GO:0071757, GO:0071753, GO:0042571, GO:0071756, GO:0005886, GO:0003823, GO:0002250, GO:0019731, GO:0050853, GO:0006958, GO:0042742, GO:0050829, GO:0045087, GO:0006911, GO:0006910, GO:0050871, IPR007110, IPR036179, IPR013783, IPR003006, IPR003597, P01871",1,7YSG,wildtype,P01871,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
7Z6U,,,,,,7Z6U,"Pose, duplicate, then elaborate: Steps towards increased affinity for inhibitors targeting the specificity surface of the Pim-1 kinase.",Pim1 in complex with (E)-4-((6-amino-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide,TRANSFERASE,PIM1,2.7.11.1,"GO:0005737, GO:0005829, GO:0005730, GO:0005654, GO:0005634, GO:0005886, GO:0005524, GO:0030145, GO:0106310, GO:0043539, GO:0004674, GO:0043024, GO:0008134, GO:0006915, GO:0007049, GO:1990748, GO:0043066, GO:0043433, GO:0090336, GO:0060045, GO:1905062, GO:0045737, GO:0045893, GO:0071902, GO:0046777, GO:0006468, GO:0050821, GO:1902033, GO:0022898, GO:0070561, IPR011009, IPR017348, IPR000719, IPR017441, IPR008271",1,7Z6U,mutant,P11309-1,UniProt,C16 H12 N2 O3,280.278,IJB,4-[(~{E})-(6-azanyl-2-oxidanylidene-1~{H}-indol-3-ylidene)methyl]benzoic acid,c1cc(ccc1C=C2c3ccc(cc3NC2=O)N)C(=O)O,4
7ZY6,,,,,,7ZY6,Identification of M4205?A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.,Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST,TRANSFERASE,,,,1,7ZY6,wildtype,,,C23 H24 N6,384.477,KCI,"5-imidazo[1,2-a]pyridin-3-yl-~{N}-[(1~{R})-1-(6-pyrrolidin-1-ylpyridin-3-yl)ethyl]pyridin-3-amine",CC(c1ccc(nc1)N2CCCC2)Nc3cc(cnc3)c4cnc5n4cccc5,2
8ADB,,,,,,8ADB,A widely distributed family of eukaryotic and bacterial deubiquitinases related to herpesviral large tegument proteins.,Viral tegument-like DUBs,HYDROLASE,wcw_1294,,"GO:0016020, IPR038765",1,8ADB,wildtype,D6YWY5,UniProt,C6 H8 O7,192.124,CIT,CITRIC ACID,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,3
8BDI,,,,,,8BDI,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 32,LIGASE,"ELOC, TCEB1",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030674, GO:0001222, GO:0016567, GO:0006357, GO:0006367, GO:0006511, IPR039948, IPR001232, IPR011333, IPR016073, Q15369",2,8BDI,wildtype,Q15369,UniProt,C29 H38 F N5 O5 S,587.706,QF7,"(2~{S},4~{R})-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-~{N}-[(1~{S})-3-(methylamino)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1c(scn1)c2ccc(cc2)C(CC(=O)NC)NC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)C4(CC4)F)O,5
8BDJ,,,,,,8BDJ,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 30,LIGASE,"ELOB, TCEB2",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030891, GO:0001222, GO:0031625, GO:0032436, GO:0016567, GO:0065003, GO:0006368, GO:0006367, IPR039049, IPR000626, IPR029071, Q15370",1,8BDJ,wildtype,Q15370,UniProt,C25 H34 Cl N3 O6,508.007,QE0,"(2~{S},4~{R})-~{N}-[(1~{S})-1-[4-chloranyl-2-(2-methoxyethoxy)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(C)c3ccc(cc3OCCOC)Cl)O,5
8BDL,,,,,,8BDL,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 27,LIGASE,"ELOC, TCEB1",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030674, GO:0001222, GO:0016567, GO:0006357, GO:0006367, GO:0006511, IPR039948, IPR001232, IPR011333, IPR016073, Q15369",2,8BDL,wildtype,Q15369,UniProt,C29 H38 N4 O6 S,570.7,QF3,"(2~{S},4~{R})-~{N}-[(1~{S})-1-[2-(2-methoxyethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(C)c3ccc(cc3OCCOC)c4c(ncs4)C)O,4
8BDM,,,,,,8BDM,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 26,LIGASE,"ELOB, TCEB2",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030891, GO:0001222, GO:0031625, GO:0032436, GO:0016567, GO:0065003, GO:0006368, GO:0006367, IPR039049, IPR000626, IPR029071, Q15370",1,8BDM,wildtype,Q15370,UniProt,C28 H36 N4 O6 S,556.674,QE9,"(2~{S},4~{R})-~{N}-[[2-(2-methoxyethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NCc3ccc(cc3OCCOC)c4c(ncs4)C)O,4
8BDN,,,,,,8BDN,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 23,LIGASE,"ELOC, TCEB1",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030674, GO:0001222, GO:0016567, GO:0006357, GO:0006367, GO:0006511, IPR039948, IPR001232, IPR011333, IPR016073, Q15369",2,8BDN,wildtype,Q15369,UniProt,C26 H31 N5 O4 S,509.62,QFR,"(2~{R})-3-methyl-1-[(2~{S},4~{R})-2-[(5~{R})-5-methyl-5-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-4~{H}-1,2,4-oxadiazol-3-yl]-4-oxidanyl-pyrrolidin-1-yl]-2-(3-methyl-1,2-oxazol-5-yl)butan-1-one",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C3=NOC(N3)(C)c4ccc(cc4)c5c(ncs5)C)O,4
8BDO,,,,,,8BDO,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,VCB in complex with compound 21,LIGASE,"ELOB, TCEB2",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030891, GO:0001222, GO:0031625, GO:0032436, GO:0016567, GO:0065003, GO:0006368, GO:0006367, IPR039049, IPR000626, IPR029071, Q15370",1,8BDO,wildtype,Q15370,UniProt,C24 H28 N4 O5 S,484.568,QFF,"(2~{S},4~{R})-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-~{N}-[4-(4-methyl-1,3-thiazol-5-yl)phenoxy]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NOc3ccc(cc3)c4c(ncs4)C)O,4
8BEB,,,,,,8BEB,Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.,"Ternary complex between VCB, BRD4-BD1 and PROTAC 49",LIGASE,"ELOC, TCEB1",,"GO:0031462, GO:0031466, GO:0005829, GO:0070449, GO:0005654, GO:0030674, GO:0001222, GO:0016567, GO:0006357, GO:0006367, GO:0006511, IPR039948, IPR001232, IPR011333, IPR016073, Q15369",2,8BEB,wildtype,Q15369,UniProt,C50 H57 Cl N10 O6 S2,993.634,QIK,"(2~{S},4~{R})-~{N}-[(1~{S})-3-[4-[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]butylamino]-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide",Cc1cc(on1)C(C(C)C)C(=O)N2CC(CC2C(=O)NC(CC(=O)NCCCCNC(=O)CC3c4nnc(n4-c5c(c(c(s5)C)C)C(=N3)c6ccc(cc6)Cl)C)c7ccc(cc7)c8c(ncs8)C)O,6
8D0A,,,,,,8D0A,TBD,Crystal structure of human USP30 in complex with a covalent inhibitor 829 and a Fab,HYDROLASE,USP30,3.4.19.12,"GO:0005829, GO:0005741, GO:0005739, GO:0005634, GO:0005778, GO:0004843, GO:0004197, GO:0101005, GO:0000422, GO:0008053, GO:1901525, GO:0000425, GO:0016579, GO:0035871, GO:0044313, GO:0006511, IPR038765, IPR001394, IPR018200, IPR028889, Q70CQ3",1,8D0A,mutant,Q70CQ3,UniProt,C21 H23 Cl N5 O S,428.958,PKH,"~{N}-[(1~{R},2~{R},4~{S},7~{E})-7-[azanyl(sulfanyl)methylidene]-7$l^{4}-azabicyclo[2.2.1]heptan-2-yl]-2-chloranyl-4-(6-cyclopropylpyrazin-2-yl)benzamide",c1cc(c(cc1c2cncc(n2)C3CC3)Cl)C(=O)NC4CC5CCC4[N+]5=C(N)S,4
8D1T,,,,,,8D1T,TBD,Crystal structure of human USP30 in complex with a covalent inhibitor 552 and a Fab,HYDROLASE,USP30,3.4.19.12,"GO:0005829, GO:0005741, GO:0005739, GO:0005634, GO:0005778, GO:0004843, GO:0004197, GO:0101005, GO:0000422, GO:0008053, GO:1901525, GO:0000425, GO:0016579, GO:0035871, GO:0044313, GO:0006511, IPR038765, IPR001394, IPR018200, IPR028889, Q70CQ3",1,8D1T,mutant,Q70CQ3,UniProt,C24 H24 Cl N4 O S,451.992,PXW,"(1R,2R,4S,7E)-7-[amino(sulfanyl)methylidene]-2-{[(1P)-3-chloro-3'-(1-cyanocyclopropyl)[1,1'-biphenyl]-4-carbonyl]amino}-7-azabicyclo[2.2.1]heptan-7-ium",c1cc(cc(c1)C2(CC2)C#N)c3ccc(c(c3)Cl)C(=O)NC4CC5CCC4[N+]5=C(N)S,4
8D6L,,,,,,8D6L,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V,TRANSPORT PROTEIN,"RBP2, CRBP2",,"GO:0005829, GO:0005634, GO:0005504, GO:0016918, GO:0005501, GO:0019841, GO:0008544, GO:0015908, GO:0006776, IPR012674, IPR000463, IPR031259, IPR000566, P50120",1,8D6L,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,"(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form",CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,3
8DB2,,,,,,8DB2,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F mutant of hCRBPII bound to synthetic fluorophore CM1V,TRANSPORT PROTEIN,"RBP2, CRBP2",,"GO:0005829, GO:0005634, GO:0005504, GO:0016918, GO:0005501, GO:0019841, GO:0008544, GO:0015908, GO:0006776, IPR012674, IPR000463, IPR031259, IPR000566, P50120",1,8DB2,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,"(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form",CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,2
8DD7,,,,,,8DD7,Cryptochrome-Timeless structure reveals circadian clock timing mechanisms.,The Cryo-EM structure of Drosophila Cryptochrome in complex with Timeless,CIRCADIAN CLOCK PROTEIN,,2.1.1.63,"GO:0003908, GO:0006304, GO:0006281, GO:0032259, IPR001497, IPR014048, IPR036217, IPR008332, IPR036631, IPR036388, GO:0005737, GO:0005829, GO:0005654, GO:0005634, GO:0048471, GO:0009882, GO:0003677, GO:0071949, GO:0050660, GO:0008020, GO:0009881, GO:0009785, GO:0071482, GO:0048512, GO:0032922, GO:0007623, GO:0050980, GO:0009649, GO:0043153, GO:0042332, GO:0045475, GO:0050958, GO:0045892, GO:0007602, GO:0042752, GO:0045187, GO:0009637, GO:0009416, GO:0071000, GO:0009588, IPR036134, IPR036155, IPR005101, IPR002081, IPR006050, IPR014729",1,8DD7,wildtype,E5BBQ0,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,3
8DN1,,,,,,8DN1,Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins.,Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V at pH 7.2,TRANSPORT PROTEIN,"RBP2, CRBP2",,"GO:0005829, GO:0005634, GO:0005504, GO:0016918, GO:0005501, GO:0019841, GO:0008544, GO:0015908, GO:0006776, IPR012674, IPR000463, IPR031259, IPR000566, P50120",1,8DN1,mutant,P50120,UniProt,C16 H19 N O2,257.328,RH6,"(2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form",CCN(CC)c1ccc2c(c1)OC(=O)C(=C2)C=CC,3
8DWL,,,,,,8DWL,Inhibitor-3 inhibits Protein Phosphatase 1 via a metal binding dynamic protein-protein interaction.,Inhibitor-3:PP1 coexpressed complex,HYDROLASE,"PPP1CA, PPP1A",3.1.3.16,"GO:0005912, GO:0005737, GO:0005829, GO:0043197, GO:0070062, GO:0098978, GO:0042587, GO:0005730, GO:0005654, GO:0005634, GO:0043204, GO:0005886, GO:0098793, GO:0000164, GO:0072357, GO:0098641, GO:0046872, GO:0017018, GO:0016791, GO:0004721, GO:0008157, GO:0004722, GO:0043021, GO:1904886, GO:0048754, GO:0007049, GO:0051301, GO:0032922, GO:0016311, GO:0043153, GO:0005977, GO:0030324, GO:0032091, GO:0070262, GO:0035970, GO:2001241, GO:0006470, GO:0060828, GO:0042752, GO:0005979, GO:0005981, GO:0036496, GO:0010288, IPR004843, IPR029052, IPR037979, IPR006186, IPR031675, P62136",1,8DWL,wildtype,P62136,UniProt,C2 H6 O2,62.068,EDO,"1,2-ETHANEDIOL",C(CO)O,4
8E8O,,,,,,8E8O,Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancer.,Cryo-EM structure of human ME3 in the presence of citrate,HYDROLASE,ME3,1.1.1.40,"GO:0005759, GO:0005739, GO:0004471, GO:0004473, GO:0004470, GO:0046872, GO:0051287, GO:0070401, GO:0008948, GO:0009060, GO:0006108, GO:0072592, GO:0006090, IPR046346, IPR015884, IPR012301, IPR037062, IPR012302, IPR001891, IPR036291, Q16798",1,8E8O,wildtype,Q16798,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,2
8EFG,,,,,,8EFG,Human and bacterial TatD enzymes exhibit apurinic/apyrimidinic (AP) endonuclease activity.,Crystal structure of human TATDN1 bound to dAMP and two zinc ions,HYDROLASE,"TATDN1, CDA11",3.1.21,"GO:0005654, GO:0008296, GO:0046872, IPR018228, IPR032466, IPR001130, Q6P1N9",1,8EFG,wildtype,Q6P1N9,UniProt,C10 H14 N5 O6 P,331.222,DA,2'-DEOXYADENOSINE-5'-MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3CC(C(O3)COP(=O)(O)O)O)N,5
8EQ4,,,,,,8EQ4,Inhibition of the proton-activated chloride channel PAC by PIP 2.,"Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8",MEMBRANE PROTEIN,"PACC1, C1orf75, TMEM206",,"GO:0009986, GO:0034707, GO:0061797, GO:0006821, IPR029366, Q9H813, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel, pH 4.0 with diC<sub>8</sub>-PI(4,5)P<sub>2</sub> using full map, Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel",1,8EQ4,wildtype,Q9H813,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
8EQ4,,,,,,8EQ4,Inhibition of the proton-activated chloride channel PAC by PIP 2.,"Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8",MEMBRANE PROTEIN,"PACC1, C1orf75, TMEM206",,"GO:0009986, GO:0034707, GO:0061797, GO:0006821, IPR029366, Q9H813, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel, pH 4.0 with diC<sub>8</sub>-PI(4,5)P<sub>2</sub> using full map, Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel",1,8EQ4,wildtype,Q9H813,UniProt,C25 H49 O19 P3,746.566,PIO,"[(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate",CCCCCCCC(=O)OCC(COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)OC(=O)CCCCCCC,3
8EWD,,,,,,8EWD,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWD,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,WZN,"{tert-butyl [1-{[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWE,,,,,,8EWE,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWE,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,X0E,"{tert-butyl [1-{[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium",CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWL,,,,,,8EWL,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWL,wildtype,P08684,UniProt,C49 H38 Ir N6 O,919.083,X1C,"{N-[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3cccc6)(c7ccccc7C8=CC=C9C=CC=CC9=[N]48)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EWM,,,,,,8EWM,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWM,wildtype,P08684,UniProt,C46 H37 F4 Ir N7 O3,1004.042,X1I,"{tert-butyl [1-{[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methylidene]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[3,5-difluoro-2-(pyridin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)N=CC2=C[N]3=C(C=C2)C4=[N]([Ir+]356(c7cc(cc(c7C8=[N]5C=CC=C8)F)F)c9cc(cc(c9C1=CC=CC=[N]61)F)F)C=CC=C4,3
8EWN,,,,,,8EWN,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWN,wildtype,P08684,UniProt,C41 H30 F4 Ir N6 O,890.927,X1O,"{N-[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[3,5-difluoro-2-(pyridin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",c1cnccc1CCC(=O)NCC2=CC=C3C4=CC=CC=[N]4[Ir+]56([N]3=C2)(c7cc(cc(c7C8=[N]5C=CC=C8)F)F)c9cc(cc(c9C1=CC=CC=[N]61)F)F,3
8EWP,,,,,,8EWP,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWP,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X2Q,"{N-[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+)",c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3sc7c6cccc7)(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]41)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EWQ,,,,,,8EWQ,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWQ,wildtype,P08684,UniProt,C56 H43 Ir N7 O2,1038.203,X2B,"{N-[1-{[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]benzamide}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",c1ccc(cc1)C(=O)NC(Cc2ccncc2)C(=O)NCC3=C[N]4=C(C=C3)C5=[N]([Ir+]467(c8ccccc8C9=[N]6c1ccccc1C=C9)c1ccccc1C1=CC=C2C=CC=CC2=[N]71)C=CC=C5,3
8EWR,,,,,,8EWR,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWR,wildtype,P08684,UniProt,C54 H47 Ir N7 O3,1034.213,WZN,"{tert-butyl [1-{[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]amino}-1-oxo-3-(pyridin-4-yl)propan-2-yl]carbamate}bis[2-(quinolin-2-yl-kappaN)phenyl-kappaC~1~]iridium(1+)",CC(C)(C)OC(=O)NC(Cc1ccncc1)C(=O)NCC2=C[N]3=C(C=C2)C4=CC=CC=[N]4[Ir+]356(c7ccccc7C8=[N]5c9ccccc9C=C8)c1ccccc1C1=CC=C2C=CC=CC2=[N]61,3
8EWS,,,,,,8EWS,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EWS,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X2Q,"{N-[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]-3-(pyridin-4-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+)",c1ccc2c(c1)C=CC3=[N]2[Ir+]45(c6c3sc7c6cccc7)(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]41)[N]1=C(C=CC=C1)C1=[N]5C=C(C=C1)CNC(=O)CCc1ccncc1,3
8EXB,,,,,,8EXB,Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4.,Crystal structure of CYP3A4 bound to an inhibitor,OXIDOREDUCTASE/INHIBITOR,"CYP3A4, CYP3A3","1.14.14.1, 1.14.14.56, 1.14.14.73, 1.14.14.55","GO:0005737, GO:0005789, GO:0043231, GO:0102320, GO:0062181, GO:0062188, GO:0062189, GO:0062187, GO:0070330, GO:0034875, GO:0019899, GO:0101020, GO:0101021, GO:0020037, GO:0005506, GO:0004497, GO:0016491, GO:0019825, GO:0050591, GO:0008401, GO:0005496, GO:0008395, GO:0050649, GO:0070576, GO:0030343, GO:0046222, GO:0009822, GO:0008209, GO:0008203, GO:0008210, GO:0046483, GO:0002933, GO:0006629, GO:0042759, GO:0016098, GO:0070989, GO:0042573, GO:0042572, GO:0006706, GO:0008202, GO:0042369, GO:0042359, GO:0042178, GO:0006805, IPR001128, IPR017972, IPR008072, IPR002402, IPR036396, P08684",1,8EXB,wildtype,P08684,UniProt,C53 H38 Ir N6 O S2,1031.255,X4E,"{N-[([2,2'-bipyridin]-5-yl-kappa~2~N~1~,N~1'~)methyl]-3-(pyridin-3-yl)propanamide}bis[2-(quinolin-2-yl-kappaN)-1-benzothiophen-3-yl-kappaC~3~]iridium(1+)",c1ccc2c(c1)c3c(s2)C4=CC=C5C=CC=CC5=[N]4[Ir+]367(c8c9ccccc9sc8C1=CC=C2C=CC=CC2=[N]61)[N]1=CC=CC=C1C1=CC=C(C=[N]71)CNC(=O)CCc1cccnc1,3
8EYO,,,,,,8EYO,Integrative structural and functional analysis of human malic enzyme 3: A potential therapeutic target for pancreatic cancer.,Crystal Structure of Human Mitochondrial NADP+ Malic Enzyme 3 with NADP bound,OXIDOREDUCTASE,ME3,1.1.1.40,"GO:0005759, GO:0005739, GO:0004471, GO:0004473, GO:0004470, GO:0046872, GO:0051287, GO:0070401, GO:0008948, GO:0009060, GO:0006108, GO:0072592, GO:0006090, IPR046346, IPR015884, IPR012301, IPR037062, IPR012302, IPR001891, IPR036291, Q16798",1,8EYO,wildtype,Q16798,UniProt,C21 H28 N7 O17 P3,743.405,NAP,NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE,c1cc(c[n+](c1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4ncnc5N)OP(=O)(O)O)O)O)O)C(=O)N,2
8F4V,,,,,,8F4V,Structural Elucidation of Ivermectin Binding to alpha 7nAChR and the Induced Channel Desensitization.,Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state,MEMBRANE PROTEIN,"CHRNA7, NACHRA7",,"GO:0005892, GO:0070161, GO:0043005, GO:0005886, GO:0044853, GO:0098794, GO:0045211, GO:0045202, GO:0042166, GO:0015464, GO:0022848, GO:0001540, GO:0005262, GO:0017081, GO:0005231, GO:0005216, GO:0030594, GO:0042803, GO:0015643, GO:1904315, GO:0095500, GO:0006816, GO:0006874, GO:0007268, GO:0050890, GO:0140059, GO:0097061, GO:0034220, GO:0006811, GO:0007611, GO:0051899, GO:0007613, GO:0098815, GO:1902430, GO:0032720, GO:0050877, GO:1902004, GO:0045766, GO:0008284, GO:1905920, GO:0070374, GO:2000463, GO:1900273, GO:0043410, GO:0051247, GO:0001934, GO:1905906, GO:1902991, GO:0042391, GO:1901214, GO:0080164, GO:1905144, GO:1904645, GO:0001666, GO:0035094, GO:0050893, GO:0007614, GO:0007165, GO:0050808, GO:0007271, IPR006202, IPR036734, IPR006201, IPR036719, IPR038050, IPR006029, IPR018000, IPR002394, P36544, Transmembrane.Alpha-helical polytopic.Pentameric ligand-gated ion channels.Ligand-gated ion channel of neurotransmitter receptors, Generic PDBTM",1,8F4V,mutant,P36544,UniProt,C48 H74 O14,875.093,IVM,"(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17
-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy
clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside",CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,2
8FBL,,,,,,8FBL,Inhibition of the proton-activated chloride channel PAC by PIP 2.,"Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8",MEMBRANE PROTEIN,"PACC1, C1orf75, TMEM206",,"GO:0009986, GO:0034707, GO:0061797, GO:0006821, IPR029366, Q9H813, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel, pH 4.0 with diC<sub>8</sub>-PI(4,5)P<sub>2</sub> using full map, Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel",1,8FBL,wildtype,Q9H813,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,2
8FBL,,,,,,8FBL,Inhibition of the proton-activated chloride channel PAC by PIP 2.,"Human PAC in nanodisc at pH 4.0 with PI(4,5)P2 diC8",MEMBRANE PROTEIN,"PACC1, C1orf75, TMEM206",,"GO:0009986, GO:0034707, GO:0061797, GO:0006821, IPR029366, Q9H813, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Other Ion Channels.proton-activated chloride (PAC/ASOR) channel, pH 4.0 with diC<sub>8</sub>-PI(4,5)P<sub>2</sub> using full map, Transmembrane.Alpha-helical polytopic.Proton-activated chloride channel.Proton-activated chloride channel",1,8FBL,wildtype,Q9H813,UniProt,C25 H49 O19 P3,746.566,PIO,"[(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate",CCCCCCCC(=O)OCC(COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)OC(=O)CCCCCCC,3
8FHN,,,,,,8FHN,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 2),MEMBRANE PROTEIN,"slc12a2, nkcc1",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHN,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,3
8FHN,,,,,,8FHN,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 2),MEMBRANE PROTEIN,"SLC12A3, NCC, TSC",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHN,mutant,P55017,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FHO,,,,,,8FHO,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 1),MEMBRANE PROTEIN,"slc12a2, nkcc1",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHO,mutant,A0A0G2KTI4,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,2
8FHO,,,,,,8FHO,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 1),MEMBRANE PROTEIN,"SLC12A3, NCC, TSC",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHO,mutant,P55017,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,3
8FHP,,,,,,8FHP,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-1),MEMBRANE PROTEIN,"slc12a2, nkcc1",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHP,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8FHQ,,,,,,8FHQ,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-2),MEMBRANE PROTEIN,"slc12a2, nkcc1",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHQ,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8FHR,,,,,,8FHR,Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter.,Cryo-EM structure of human NCC (class 3-3),MEMBRANE PROTEIN,"slc12a2, nkcc1",,"GO:0016324, GO:0016323, GO:0008519, GO:0015377, GO:0042802, GO:0015379, GO:0008511, GO:0006884, GO:0055064, GO:1902476, GO:0043583, GO:0042472, GO:0055075, GO:1990573, GO:0055078, GO:0035725, GO:0048798, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842, GO:0005829, GO:0070062, GO:0016020, GO:0005886, GO:0015081, GO:0015378, GO:0071241, GO:0006811, GO:0006468, GO:1904044, GO:0002021, GO:0007165, GO:0006814, IPR002948, P55017, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Amino Acid/Polyamine/Organocation (APC) Superfamily.NCC cation-chloride cotransporter (CCC), Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Cation-chloride cotransporter, Generic PDBTM",1,8FHR,mutant,A0A0G2KTI4,UniProt,C11 H13 Cl F3 N3 O4 S3,439.882,XZF,Polythiazide,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,2
8HHY,,,,,,8HHY,Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.,SARS-CoV-2 Delta Spike in complex with IS-9A,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8HHY,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,5
